1. Home
  2. IFRX vs AMPY Comparison

IFRX vs AMPY Comparison

Compare IFRX & AMPY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.42

Market Cap

225.5M

Sector

Health Care

ML Signal

HOLD

Logo Amplify Energy Corp.

AMPY

Amplify Energy Corp.

HOLD

Current Price

$3.53

Market Cap

199.8M

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
IFRX
AMPY
Founded
2007
2011
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
225.5M
199.8M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
IFRX
AMPY
Price
$1.42
$3.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
2
Target Price
★ $8.36
$7.75
AVG Volume (30 Days)
★ 983.2K
482.0K
Earning Date
11-03-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 232.26
EPS
★ N/A
N/A
Revenue
N/A
★ $208,637,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.75
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.80
$3.65
52 Week High
$2.95
$6.79

Technical Indicators

Market Signals
Indicator
IFRX
AMPY
Relative Strength Index (RSI) 46.69 28.83
Support Level $1.58 $3.65
Resistance Level $2.44 $4.22
Average True Range (ATR) 0.12 0.17
MACD 0.04 -0.07
Stochastic Oscillator 66.34 1.18

Price Performance

Historical Comparison
IFRX
AMPY

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About AMPY Amplify Energy Corp.

Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.

Share on Social Networks: